Inspire Dry Eye Drug Fails Key Test: BioBuzz - TheStreet

Inspire Dry Eye Drug Fails Key Test: BioBuzz

Phase III study of Prolacria misses primary and secondary endpoints.
Author:
Publish date:

DURHAM, N.C. (

TheStreet

) --

Inspire Pharmaceuticals

(ISPH)

said Thursday its experimental drug Prolacria for dry eye disease failed to meet the primary or secondary goals of a phase III study.

"We have provided the top-line results from this trial to our partner

Allergan

(AGN) - Get Report

and we will be conducting a thorough review of the program before determining next steps, if any," said Inspire CEO Christy Shaffer, in a statement.

The U.S. Food and Drug Administration has twice turned down Inspire's previous efforts at getting Prolacria approved.

Inspire shares closed Wednesday at $6.61.

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on

Twitter

.

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

click here

to send him an email.